CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Adult participants 19 years of age or older
• Participants who receive mavacamten according to the approved product label
• Participants who sign the informed consent form
Locations
Other Locations
Republic of Korea
Local Institution - 0001
TERMINATED
Seoul
Novotech Laboratory Korea Co., Ltd.
RECRUITING
Seoul
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2024-07-24
Estimated Completion Date: 2026-11-30
Participants
Target number of participants: 600
Treatments
Participants receiving mavacamten for oHCM
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb